Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further characterize active compounds and optimize their potency and selectivity to generate lead molecules for subsequent progression into clinical trials.
This contract expands Evotec’s existing collaboration with InterMune which was initiated in early 2007. This collaboration applies Evotec’s fragment-based drug discovery platform, EVOlution, in combination with their ultra-high-throughput screening technologies to InterMune’s targets. The financial terms include a technology access fee for access to Evotec’s fragment-based drug discovery platform, EVOlution, plus ongoing research funding.